中新网上海2月11日电 (记者 陈静)记者11日在此间获悉，来自中国的五官健康C909飞机医院首次飞出国 门抵达老挝首都万象，开展以飞机医院为纽带，链接当地医院、学校的系列卫生健康公益项目。 此次五官健康C909飞机医院"空中健康丝绸之路"老挝公益项目集义诊筛查、联合门诊、公益手术、医 学教学、健康科普等为一体，将优质医疗资源直接送达湄公河畔，为2026年中老建交65周年暨中老友好 年写下温暖开篇。 上海专家为老挝民众做手术。(复旦大学附属眼耳鼻喉科医院供图) 中国专家在玛霍索综合医院坐诊时，前来就诊的民众在四楼五官科门诊厅外早早等候着，大多是白发苍 苍的长者。诊室大厅经过特别的布置，从上海运载而来的角膜地形图、眼科生物测量仪和由中国捐赠的 角膜内皮镜一字排开，为老挝民众提供精确的白内障术前检查。来自复旦大学附属眼耳鼻喉科医院的中 方医疗队员与老挝医护人员并肩坐诊。"听(老挝)医生说中国医生要来，我等了很久。"一位老奶奶说。 她在孙女的陪同下前来就诊。中方专家耐心地检查视力、排查眼底疾病，对需要手术的患者逐一登记， 而老挝医护人员则在一旁认真记录、学习，遇到疑问便及时请教。 在具有悠久历史的玛霍索综合医院的老 ...

Group 1 - The China Eye Health Industry Park Alliance was established during the conference, aiming to create a collaborative mechanism among leading eye health industry parks in China [1][3] - The conference emphasized the theme of "Ecological Co-construction and Win-win Cooperation," focusing on collaboration in areas such as industrial park synergy, open sharing of innovative resources, and efficient transformation of technological achievements [1][2] - The Changping District has developed a comprehensive industrial chain in the medical and health sector, with nearly 3,000 health enterprises and an industry revenue exceeding 100 billion yuan [1][2] Group 2 - The International Smart Medical Engineering Innovation Center was established to integrate clinical needs, research innovation, and industrial transformation, gathering key companies in the eye health sector [2][3] - The center aims to enhance the development of high-end ophthalmic instruments and medications, promoting the establishment of a leading eye health industry cluster in China [2][3] - The center is supported by various organizations, including Tsinghua University and the China Medical Equipment Association, and is located in the International Medical Device City in Changping District [3] Group 3 - Tupu Medical, founded in 2017, is one of the largest ophthalmic medical device companies in China, with a comprehensive product line that competes with global leaders [4] - The company has established a strong presence in multiple cities and focuses on high-end ophthalmic equipment, including OCT and surgical microscopes [4] - Tupu Medical is recognized for its ability to compete with Zeiss across its entire product line, positioning itself as a full-platform supplier of high-end ophthalmic instruments [4]

Core Viewpoint - The innovation drug sector is gradually recovering, leading to valuation restoration in both A-share and Hong Kong markets, driven by regulatory optimization, stable medical insurance payment policies, and positive international clinical trial results [1] Group 1: Investment Focus - The company has concentrated its investments in hard technology, artificial intelligence, and medical fields, with representative projects in gene cell therapy, high-end ophthalmic equipment, and surgical robots, which are poised to benefit from the recovery cycle of innovative drugs [2] - In the cell therapy sector, the company invested in Yimiao Shenzhou, a local enterprise that has achieved a full-process serum-free CAR-T technology, enhancing the clinical application prospects of cell therapy products [2] Group 2: High-end Medical Devices - The company’s investment in TUPAI Medical, a domestic ophthalmic equipment platform, has led to it achieving the highest market share in domestic OCT products and entering a sales acceleration phase with its ophthalmic surgical microscope [3] - TUPAI Medical is expanding from diagnostic to therapeutic devices, establishing a foundation for an intelligent surgical platform in ophthalmology and other clinical areas [3] Group 3: Policy and Market Dynamics - The medical health sector is entering a new cycle of dual benefits from policy and market, with national emphasis on high-end medical devices and self-innovated drugs [4] - The company’s investment strategy focuses on key technological nodes and deep engagement with important enterprises, which may lead to positive impacts on its fundamentals and market image as main funds return to the innovative drug and medical technology sectors [4]

Core Insights - The article highlights the increasing participation of domestic medical equipment in the ophthalmology sector, particularly in basic examinations, auxiliary diagnostics, AI imaging, and surgical support equipment, indicating a shift towards domestic and AI-driven solutions in the market [1][3]. Summary by Sections Market Trends - The procurement trends for the second half of the year will focus on domestic production, AI integration, and penetration into lower-tier markets [1]. Procurement Overview - In the past week, there were 13 different procurement units involved, including top-tier hospitals and county-level hospitals, indicating a diverse range of buyers [3]. - The procurement involved nearly 20 different types of ophthalmic equipment, covering basic examination tools, imaging and diagnostic devices, and surgical treatment instruments [3]. Brand Participation - A total of 22 brands were involved in the procurement, with domestic brands accounting for nearly 60% of the total, showcasing the growing influence of local manufacturers [3]. Financial Highlights - The total bid amount reached 18.743 million yuan, with the highest single equipment bid amounting to 3.2779 million yuan, reflecting significant investment in ophthalmic technology [3].

将向科创板眼科医疗设备"第一股"发起冲击。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，图湃医疗日前完成由社保基金中关村自主创新专项基金(由君联资本担任管理 人)、北京机器人产业投资基金、启明创投共同投资的总规模达5亿元人民币级别E轮融资。 这是继2024年6月完成D轮融资后，图湃医疗一年内再受顶级投资机构青睐。 ， 也是 国内 眼科医 疗设备领域历史上已公开一级市场投融资事件中单笔金额最高的融资 ，所融资金将持续用于图湃医 疗丰富产品矩阵及加强全球范围的市场布局等。 在完成本次E轮融资后，图湃医疗将向科创板眼科医疗设备"第一股"发起冲击。 图湃医疗始于清华大学电子工程系的科技成果转化。公司创始人、清华大学霍力教授2008年在约翰 霍普金斯大学做博士后期间就开始从事扫频OCT研究，师从Xingde Li教授，后者是OCT发明人 James G. Fujimoto教授的学生。在国家自然科学基金等多个科研项目的支持下，霍力教授带领团 队实现了一系列关键底层技术的突破和自主化。 图湃医疗成立后，眼科OCT在北京清华工业开发研究院医工转化体系中，迅速完成 ...